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Pertussis known as whooping cough is a highly contagious disease. Whole cell pertussis vaccine is the most economical 
and effective strategy for preventing and controlling pertussis. The efficacy of whole cell vaccine is ascertained most 
commonly by intracerebral challenge assay, but it does not reflect the true efficacy of vaccine as Pertussis essentially is a 
respiratory disease. Therefore, in order to mimic the natural infection, intranasal challenge model in mice was developed. In 
intranasal challenge assay mice were immunized with vaccine and challenged through intranasal route. Mice lungs were 
dissected and examined for bacterial count. The degree of count was related to efficacy of vaccine, higher count indicated 
low efficacy and low count pointed to better efficacy.  
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Introduction 
Bordetella Pertussis is the causative agent of 
disease pertussis, also known as whooping cough or 
cough of 100 days
1
. In the last two decades, 
epidemiology of pertussis has noticeably changed, 
with a shift of cases to adolescents, adults and 
children too young to have completed their infant 
immunization series
2
. This resulted in higher infant 
mortality
3
. Vaccination is the most economical and 
effective strategy for preventing and controlling 
pertussis
4
. The whole cell pertussis vaccines should 
contain agglutinogen 2 and 3 to produce vaccines 
with very high efficacy. Agglutinogen 1 (agg 1) 
antigen which is present on fimbriae and cell surface 
of pertussis vaccine strains is not well studied for its 
protective role. Hence, in the present study an  
attempt has been made to investigate the role of agg 1 
in intranasal challenge assay and intracerebral 
challenge assay. 
 
Materials and methods 
 
Bordetella pertussis 353 vaccine preparation: 
B.pertussis 353 strain was obtained from 
Department of Molecular Genetics, University of 
Cincinnati, USA and vaccine was produced at Serum 
Institute of India Pvt. Ltd., Pune. A freeze dried 
ampoule was reconstituted and used to inoculate 
growth medium. The bacterial suspension was 
centrifuged at 7000 rpm for 30 minutes in a cold 
centrifuge. Cell mass thus obtained was harvested in 
200 ml 0.02 % thiomersal saline and inactivated at  
56 °C for 15 minutes in a shaker water bath. 
Inactivated cell suspension was checked for opacity 
by measuring OD, purity by growth on nutrient  
agar plates, viability by growth on BG agar plates  
and presence of agglutinogen antigens by slide 
agglutination method. Safety of this vaccine was 
established in mouse weight gain test and test for 
absence of dermonecrotic toxin (DNT) 
5
. Vaccine was 
stored at 2-8 °C for further use in the study. 
Points considered while developing Intranasal 
Challenge Assay (INCA) 
• Mice strain selection, 
• Selection of dilution for immunization, 
• Selection of method for Challenge preparation. 
 
Mice strain selection 
NIH, Balb/c and Swiss albino female mice,  
6-8 weeks of age were bred and maintained at  
Serum Institute of India Pvt. Ltd. (Siipl), Pune, India, 
animal house. Animals were kept in well ventilated 
cages and with free access to food palettes and water. 
Unimmunized mice of each strain were taken  
in a group and were challenged with 25 µl  
virulent Bordetella pertussis 18323 strain intranasaly. 
A challenge dose of 2x10
8
 organism/ ml was used in 
———— 
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the study. Six mice of each strain were dissected for 
lungs after 2 hrs of challenge and remaining six after 
7 days of challenge. Dissected lungs were then 
homogenised and plated on BG agar plates. Plates 
were incubated at 37 °C for 4 days and CFU (Colony 
Forming Unit) count was done. 
 
Selection of method for Challenge preparation 
Bordetella pertussis 18323 challenge preparation 
was prepared by spectrophotometer method and liquid 
nitrogen method. In spectrophotometer method, 
lyophilized tube of challenge organism was opened 
and revived on BG agar slant. After second  
passage the growth was harvested and diluted to 
contain 10 IOU as measured spectrophotometrically.  
A dilution which contained 10 IOU is further  
diluted to contain 2x10
8
 organisms. Liquid nitrogen 
challenge preparation at 10 IOU was prepared as 
described previously
 6
 and further diluted to contain 
2x10
8
 organisms.  
 
Selection of dilution for immunization 
Bordetella pertussis RWRS vaccine with assigned 
unitage of 63 IU, which contain agg 1, 2 & 3 was 
used for immunizing a group of six mice 
intraperitoneally at 4 IU/ml and 0.2 IU/ml 
concentration. But no bacterial count was observed at 
4 IU/ml in lung homogenates, so a low dose range of 
0.2 IU/ml and 0.04 IU/ml was used in following 
experiments. Bordetella pertussis 353 strain was first 
diluted to 32 IOU and then immunized at 1:2 and 1:40 
dilution. Very low bacterial count was observed at 1:2 
dilution of immunization. Therefore a higher dilution 
range of 1:8 and 1:40 was used in further 
experiments. A comparison of Bordetella pertussis 
353 vaccine efficacy in terms of lung CFU count was 
also made in intranasal challenge assay with Siipl 
pertussis vaccine production strains e.g. Bp1, Bp2 and 
Bp3 at 1:8 and 1:40 dilution of immunization.  
 
Intracerebral challenge assay 
Intracerebral challenge assay was performed in 
Swiss albino mice as per method described in WHO 
TRS 941
5
. Potency of B. pertussis 353 vaccine 
preparation was estimated against working standard 
and compared with Bp1, Bp2 and Bp3. 
 
Results and Discussion 
 
Bordetella pertussis 353 vaccine preparation: 
Opacity of 205 IOU was assigned to B pertussis 
353 vaccine preparation. This vaccine was shown to 
contain only agglutinogen 1 as it showed positive 
reaction with NIBSC reference anti agglutinogen 1 
serum and not with anti agglutinogen 2 and anti 
agglutinogen 3 serum. The vaccine was found safe in 
mouse weight gain test as 90.18% weight gain against 
a passing criterion of 60% was observed. The vaccine 
was also checked for absence of DNT and no 
dermonecrosis in nuchal region of suckling mice was 
seen after administering the vaccine. 
 
Mice strain selection 
Unimmunized NIH, Balb/c and Swiss albino mice 
were dissected after 2 hrs of challenge and the CFU 
count obtained after plating their lung homogenates 
indicated that initial infection had been established 
(Figure 1). An increased count was observed when 
remaining mice in each strain group were dissected 
after 7 days of challenge. The highest increase was 
recorded for NIH mice strain and amounting to 2.1 
log10. For Balb/c mice strain, the difference between 
CFU count after 2 hrs and 7 days of challenge was 1 
log10 and in case of Swiss albino this difference was 
1.53 log10. But in case of Swiss albino mice, the count 
was found least among all three mice strains in both 
initial as well as after 7 days of challenge (Figure. 1). 
 
Selection of method for Challenge preparation 
Two methods for challenge preparation viz liquid 
nitrogen and spectrophotometer were evaluated in 
INCA. Initially after 2 hrs of challenge almost similar 
bacterial count was observed for both the preparation 
whereas after 7 days of challenge a slightly higher 
count was observed for liquid nitrogen preparation 
and the difference in CFU count was 1.18 log10 
(Figure 2). 
 
Selection of dilution for immunization 
Freshly reconstituted Bordetella pertussis RWRS 
vaccine with an assigned unitage of 63 IU was 
assayed in INCA in two separate experiments. In first 
 
 
Fig. 1 — NIH, Balb/c and Swiss albino mice strain evaluation for 
sensitivity to Bordetella pertussis 18323 infection after intranasal 
challenge (Data represents Means ± SE). 
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experiment, 4 IU/ml and 0.2 IU/ml concentrations 
were used to immunize mice intraperitoneally. Total 
bacterial clearance at 4 IU/ml concentration was 
obtained and at 0.2 IU/ml concentration the CFU 
count was found to be 2.43 log10. Since there was a 
measurable response at only  0.2  IU/ml  dose,  it  was 
decided to immunize mice at 0.2 IU/ml and 0.04 
IU/ml dose level in the next experiment. An increase 
in bacterial count from 1.83 log10 to 3.52 log10 was 
seen as dose of vaccine was reduced from 0.2 IU/ml 
to 0.04 IU/ml. Similarly, Bordetella pertussis 353 
vaccine was immunized at 1:2 and 1:40 dilution after 
normalizing it to 32 IOU. A count of 1.08 log10 
increased to 1.88 log10 as vaccine dilution was 
increased from 1:2 to 1:40. In the next experiment, 
Bordetella pertussis 353 vaccine was immunized with 
a difference of 5 fold in two dilutions i.e.1:8 and 1:40. 
A CFU count of 1.48 log10 and 2.32 log10 was 
observed for dilution 1:8 and 1:40 respectively. The 
observed CFU count was dose dependent as high dose 
of vaccine resulted in low CFU count and low dose in 
high count. The protective capacity of Bordetella 
pertussis 353 vaccine (which contain agglutinogen 1 
only) against infection was compared with Siipl 
pertussis vaccine production strains Bp1 (contain 
agglutinogen 1 & 3), Bp2 (contain agglutinogen 1 & 2) 
and Bp3 (contain agglutinogen 1, 2 & 3). An 
unimmunized mice group was also included in the 
study. All pertussis vaccines were first normalized to 
32 IOU and then used at 1:8 and 1:40 dilution to 
immunize allocated group of six mice. At 1:8 dilution 
a mean CFU count of 1.33 log10 was observed for 
Bordetella pertussis 353 vaccine and this increased to 
2.97 log10 at 1:40 dilution. Unimmunized mice group 
showed a lung CFU count of 3.26 log10 after 7 days of 
challenge. In case of Bp1, Bp2 and Bp3 strain total 
lung clearance was observed at 1:8 dilution for 
immunization (Figure. 3). In 1:40 dilution, a lung 
CFU count of 1.59 log10, 2.79 log10 and 2.0 log10 was 
observed for Bp1, Bp2 and Bp3 vaccine respectively 
(Figure 3). 
In intranasal challenge assay Bordetella pertussis 
353 vaccine which contains agg 1 only, conferred 
protection as indicated by low CFU count
7
 in 
comparison to unimmunized control group. The 
protection against lung infection was dose dependent 
which was also reported earlier by Xing et al.
8
 in 
aerosol challenge model. But this protective efficacy 
was inferior to Siipl pertussis vaccine production 
strains Bp1, Bp2 and Bp3. This may be due to 
presence of agg 2 and/or agg3 in addition to agg 1 on 
these strains as azgg 2 and agg 3 antigens were found 
to confer protection by Gorringe et al.
9
. Potency of 
Bordetella pertussis 353 vaccine was also estimated 
in an intracerebral challenge assay, which is the only 
test that had shown a correlation with protection in 
children
10
. Results in agreement with the intranasal 
challenge assay were obtained where Bordetella 
pertussis 353 showed a low mean potency of 2.34 
IU/dose in comparison Bp1, Bp2 and Bp3 vaccine 
strains, which showed a potency of 5.76 IU/dose,  
7.95 IU/dose and 7.05 IU/dose respectively.  
Since B. pertussis 353 vaccine used in the study was a 
whole cell preparation and it contain many other 
antigens in addition to agglutinogen 1, the protection 
observed in both challenge assays could be attributed 
to their presence. 
 
Conclusion 
In the present research work, Intranasal Challenge 
Assay (INCA) was developed and protective capacity 
of Bordetella pertussis 353 vaccine, which contains 
agg 1 only was evaluated. Three mice strains NIH, 
 
 
Fig. 2 — Comparison of Liquid nitrogen and Spectrophotometer 
method (Data represents Means ± SE). 
 
 
 
Fig. 3 — Protective capacity of Bordetella pertussis 353 vaccine 
in intranasal challenge assay in terms of CFU log10 count was 
compared with unimmunized control group and with Siipl 
pertussis vaccine production strains Bp1, Bp2 and Bp3. 
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Balb/c and Swiss albino were evaluated for use in 
INCA. Although initial lung infection or colonization 
was slightly higher for Balb/c strain as compared to 
NIH strain, but the extent of propagation of infection 
was highest for NIH strain. Swiss albino mice strain was 
found to be least sensitive since lung CFU count after 2 
hrs and 7 days of intranasal challenge was least among 
three mice strains. Based on these results NIH mice 
strain was selected for use in INCA. Two methods liquid 
nitrogen and spectrophotometer method were evaluated 
for intranasal challenge preparation. The challenge 
preparation which was made using liquid nitrogen 
method, CFU count after 7 days of challenge was higher 
as compared to spectrophotometer method. Liquid 
nitrogen method was used in further experiments since 
better lung colonization was achieved in this method. 
Novotny et al.
6 
had also used single lot of frozen 
Bordetella pertussis 18323 challenge strain and this 
method provides additional advantage of controlling the 
assay variation. 
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